Skip to main content

CD371-specific/YSNVz/I-18 CAR T cells

CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia

  • RegistryNCT06017258
  • PhasePhase 1
  • StatusRecruiting
  • ConditionRefractory Acute Myeloid Leukemia
  • SponsorMemorial Sloan Kettering Cancer Center
How CD371-specific/YSNVz/I-18 CAR T cells worksNCT060172581 min

What the film says

Read the transcript

CAR T cells transformed lymphoid leukemias. In acute myeloid leukemia they have mostly failed: the cells tire, and the leukemia carries on.

The idea: a receptor built to resist exhaustion, on cells that also pump out their own alarm signal.

At Memorial Sloan Kettering, a patient's T cells get a receptor for CD371, a marker on AML cells, with an altered signaling domain to slow burnout, plus a gene to secrete interleukin-18, which rallies other immune cells.

In the first five patients, the cells expanded from one small infusion. Three, each refractory to five or more prior treatments, cleared their leukemia. Two at the higher dose had serious side effects, so the dose was reduced.

Mark Geyer leads it. Public record; not medical advice.

Sources behind this film

The drug

What is being tested.

Cohorts will be infused with escalating doses of CD371-specific/YSNVz/IL-18 CAR T cells with lymphodepleting chemotherapy (LDC) to establish the maximum tolerated dose (MTD). There is a third, lower dose level (step-down dose) available for dose de-escalation in the event of severe toxicity at the first planned dose level.

The study

How the trial runs.

The purpose of this study is to find out whether CD371-YSNVZ-IL18 CAR T cells are safe, and to look for the highest dose of CD371-YSNVZ-IL18 CAR T cells that cause few or mild side effects in participants.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Subject Inclusion: Collection of T cells (Part A)
  • History of CD371+ AML
  • Any disease status is eligible for collection
  • Expression of CD371 at any level on AML blasts (any method of detection including IHC and/or flow cytometry)
  • Pediatrics: ≥ 1 year and ≥ 10kg for collection
  • Adults: no limit on age/weight for collection

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.